Ireland-based developer of the ProVee System for BPH, a minimally invasive solution for treating benign prostatic hyperplasia (BPH)
ProVerum has raised €68M across 1 funding round from 7 investors, most recently a Series B round in Aug 2025. Based in Dublin, Ireland; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-08-25 | Series B | €68M |
| Atlantic Bridge,Enterprise Ireland,Gilde Healthcare Partners,Ireland Strategic Investment Fund (ISIF),Lightstone Ventures,MVM Partners+1 more |
| View deal → |
